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Abstract 
BACKGROUND: Pomegranate juice (PJ) is rich in bioactive phytochemicals with antioxidant, 
and anti-inflammatory and cardioprotective functions. The present trial investigated the acute 
effects of PJ consumption on blood pressure and markers of endothelial function. 
METHODS: In this single-arm study, thirteen hypertensive men aged 39–68 years were 
recruited. Included subjects were assigned to natural PJ (150 ml/day) following a 12 hour fast. 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and flow-mediated dilation 
(FMD), along with serum concentrations of C-reactive protein (CRP), intracellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and interleukin-6 
(IL-6) were measured at baseline and 4-6 hours after PJ consumption. 
RESULTS: Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP 
(7%; P = 0.013) and DBP (6%; P < 0.010). However, changes in FMD (20%) as well as 
circulating levels of CRP, ICAM-1, VCAM-1, E-selectin, and IL-6 did not reach statistical 
significance (P = 0.172). 
CONCLUSION: PJ has promising acute hypotensive properties. Consumption of PJ could be 
considered in the context of both dietary and pharmacological interventions for hypertension. 
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Introduction 
Cardiovascular disorders are among the leading 
causes of death and disability in the world.1,2 
Hypertension is a major risk factor for 
cardiovascular and cerebrovascular disease, end 
stage renal disease, type 2 diabetes, and metabolic 
syndrome. Hypertension has a high global 
prevalence of about 15% that is estimated to reach 
as high as 30% by 2025.3,4 Controlled studies have 
indicated that each 5 mmHg decrease in diastolic 
blood pressure (DBP) is associated with 15% and 
40% reductions in the risk of cardiovascular disease 
and stroke, respectively.5 In spite the introduction 
of several classes of anti-hypertensive agents with 
different mechanisms of action, uncontrolled 
hypertension resistant to drug therapy still remains a 
frequent medical problem.  
Pomegranate (Punica granatum L.; Family 
Punicaceae) is a popular edible fruit with wide 
applications in traditional medicine.6,7 Several lines of 
modern scientific evidence have also indicated the 
therapeutic efficacy of pomegranate against different 
types of disorders.8-11 The pomegranate is 
characterized by considerable amounts of biologically 
active phytochemicals including flavonoids (e.g. 
anthocyanins, catechins, quercetin, and rutin), other 
types of polyphenols, ellagitannins, and antioxidant 
vitamins.12-15 Many of these phytochemicals have 
been shown to possess antioxidant and anti-
inflammatory properties plus additional biological 
activities such as inhibition of angiotensin 
converting enzyme.16-20 All these activities of the 
pomegranate are potentially beneficial for the 
treatment of hypertension and improvement of 
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endothelial function.11 However, clinical studies 
investigating the hypotensive and cardioprotective 
effects of pomegranate have been scarce.20-26 
According to the Seventh Report of the Joint 
National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure 
(JNC7), prehypertension is defined as 120 mmHg ≤ 
systolic blood pressure (SBP) < 140 mmHg 12 
and/or 80 mmHg ≤ DBP < 90 mmHg.27 
Prehypertension is a clinical stage where subjects are 
at increased risk (2 folds higher) of developing 
hypertension in the near future.28 Emerging findings 
suggest that interventions at the prehypertension 
stage can prevent or delay the progression of disease 
into established hypertension and subsequent 
detrimental outcomes.29 The present trial investigated 
the acute effects of pomegranate juice (PJ) on blood 
pressure and endothelial function in subjects with 
diagnosed prehypertension. 
Materials and Methods 
Subjects 
Thirteen hypertensive men aged 39–68 years were 
recruited for this trial.30 The Ethics Committee at 
the Shahrekord University of Medical Sciences 
(Iran) approved the study protocol (code: 92-3-16) 
and written informed consents were obtained from 
all participants. 
The inclusion criteria were body mass index 
(BMI) ≤ 30, and diagnosed hypertension defined as 
SBP > 120 mmHg and/or DBP > 80 mmHg. 
Exclusion criteria were type 1 or 2 diabetes, chronic 
pancreatitis, liver cirrhosis, kidney stones, renal 
failure, use of non-steroidal anti-inflammatory 
drugs, use of antioxidant or vitamin supplements, 
intense physical activity (> 5 h/week), smoking 
habit, being vegetarian or having any restrictive 
dietary requirements, and pregnancy.  
Study design 
The present study was designed as a single-arm 
clinical trial. The included subjects were assigned to 
natural PJ (150 ml/day) following a 12-h fast. SBP, 
DBP, and flow-mediated dilation (FMD), along 
with serum concentrations of C-reactive protein 
(CRP), intracellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1), E-
selectin, and interleukin-6 (IL-6) were measured at 
baseline and 4-6 h after PJ consumption. 
Participants were asked not to eat or drink anything 
during the interval between PJ consumption and 
final measurements. 
Total anthocyanin assay 
A pH differential method was carried out to 
determine the total anthocyanin content of PJ. In 
this method, the difference in the absorbance of 
sample at pHs 1.0 and 4.5 is proportional to the 
total anthocyanin content. Details of this method 
have been published previously.24,31 
Anthropometric and BP measurements 
Measurement of weight and height was carried out 
using a standard procedure as described previously.24,32 
Body mass index (BMI) was calculated as weight in kg 
divided by height in meters squared (m2). BP was 
measured by a single operator at baseline and 4-6 h 
after intake of PJ, according to a standard protocol. BP 
recordings were performed after rest, employing a 
stethoscope and calibrated sphygmomanometer 
(Accurtorr 1A; Datascope, Japan). Systolic blood 
pressure was defined as the appearance of the first 
sound (Korotkoff phase 1) and diastolic blood 
pressure was defined as the disappearance of the 
sound (Korotkoff phase 5) during deflating of the 
cuff.24,32 
FMD measurement 
Endothelium-dependent FMD was measured on the 
right brachial artery as described previously.33All 
measurements were carried out by a single operator 
following a 5-min rest and employing a GE vivid 3 
ultrasound apparatus (AtCor Medical, Solingen, 
Germany). A BP cuff was inflated around the 
forearm to 200 mmHg for 5 min. Images were 
recorded at baseline (before inflation), 30 s before 
cuff release, and then every 15 sec after cuff release 
for 3 min. Arterial diameter was measured at the 
end of end-diastolic phase, coinciding with R-wave 
on the electrocardiogram (ECG). Brachial FMD 
was expressed as the percentage change in arterial 
diameter from baseline.34 
Blood sampling and biochemical analyses 
Twelve-hour fasted blood samples were taken from 
the left antecubital vein. After being allowed to clot 
for 2-3 h, serum was isolated by centrifugation at 
3500-4000 rpm for 10 min. Serum samples were kept 
at -80°C prior to biochemical analyses. Biochemical 
analyses were performed using an automated 
enzymatic assay (Pars Azmoon, Tehran, Iran) on a 
Hitachi 902 autoanalyzer (for CRP), or enzyme-
linked immunosorbent assay (ELISA) with 
commercial kits (Boster Biological Technology Ltd., 
Wuhan, China) (for ICAM-1, VCAM-1, E-selectin, 
and IL-6). Inter-assay coefficients of variation for 
ICAM-1, VCAM-1, E-selectin and IL-6 were 4.1-
6.4%, 6.1-7.7%, 6.6-8.1%, and 3.1-5.5%, respectively. 
Intra-assay coefficients of variation for ICAM-1, 
VCAM-1, E-selectin, and IL-6 were 3.4-5.1%, 2.3-
3.7%, 5.2-6.9%, and 2.3-4.9%, respectively. 
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Statistical analysis 
All statistical analyses were performed using SPSS for 
Windows (version 17; SPSS Inc., Chicago, IL, USA). 
Data wereexpressed as mean ± SD. Group 
comparisons were made using paired t-test (in case of 
normally distributed data) or Wilcoxon signed-ranks 
test (in case of non-normally distributed data). A 
two-sided P-value of < 0.05 was considered to be 
statistically significant. 
Results 
This trial was a comprised of 13 hypertensive male 
adolescents with a mean age, weight, and BMI of 
55.92 ±7.92 yrs, 80.42 ± 11.01 kg, and 27.34 ± 3.82 
kg/m2, respectively. All 13 subjects completed the 
study. Total anthocyanin content of PJ was 
determined to be 5.8 mg per 100 ml of the 
administered juice. 
Comparison of pre- vs. post-trial values revealed 
a significant reduction in both SBP  
(P = 0.013) and DBP (P = 0.010), amounting to an 
approximate reduction by 7% and 6%, respectively. 
However, percentage changes in FMD (20%) was 
not found to be statistically significant (P = 0.172). 
In the same manner, there was no significant 
difference in the circulating concentrations of 
inflammatory biomarkers namely hsCRP 
(P = 0.263), ICAM-1 (P = 0.248), VCAM-1  
(P = 0.657), E-selectin (P = 0.182), and IL-6  
(P = 0.763) following consumption of PJ. Baseline 
and post-trial values for the evaluated parameters 
are summarized in table 1. 
Discussion 
The present pilot trial is one of the few clinical 
evidences on the acute hypotensive and vascular 
effects of PJ. The results indicated amelioration of 
both SBP and DBP following consumption of a 
single dose of PJ. In a previous study, Aviram and 
Dornfeld investigated the effects of 2-week 
supplementation with PJ (50 ml/day) on the SBP of 
hypertensive patients.20The findings revealed a 
significant decrease in SBP amounting to 5%. In the 
same study, a 36% decrement in the activity of 
serum angiotensin converting enzyme (ACE) was 
reported from PJ.20 
The same group also investigated the effect of 
chronic supplementation with PJ (50 ml/day) in 
patients with carotid artery stenosis. Their results 
indicated a significant reduction in SBP, but not 
DBP, starting from 1 month after starting 
supplementation and generally increasing up to 
month 12 (equivalent to 12%decrement). However, 
no further reduction was observed when 
supplementation was continued for another 2 years.21 
Another study conducted by Lynn et al. indicated a 
significant reduction in both SBP and DBP following 
consumption of PJ (330 ml/day) by healthy subjects 
for 4 weeks.22 Mathew et al. reported that 
consumption of pomegranate extract, either during or 
15 min before a high-fat meal, can effectively prevent 
postprandial SBP rise at 2 and 4 h postprandial. 
Nevertheless, no significant effect was found on 
DBP.23In a recent trial conducted by our group, the 
effects of a 2-week intake of PJ (from the same source 
as that used in the present study) were evaluated on 
BP of hypertensive subjects. Our results implied a 
significant reduction of both SBP (5%) and DBP 
(4.5%) compared to the control group who consumed 
water instead of PJ.24Although most of the findings by 
previous trials infer the hypotensive impact of PJ 
consumption, there are some contrasting findings that 
are worth attention. Kelishadi et al. investigated the 
acute (4 h) and chronic (1 month) effects of PJ  
(240 ml/day) on BP of adolescents with metabolic 
syndrome and could not find any significant effect.25 
In another trial, administration of PJ (240 ml/day) for 
3 months was not found to significantly affect SBP or 
DBP in patients with stable coronary heart disease 
(CHD), as reported by Sumner et al.26 These negative 
 
Table 1. Acute effects of pomegranate juice on blood pressure, flow-mediated dilation, and biochemical parameters 
Parameters Before After P 
SBP (mmHg) 125.38 ± 11.80 116.15 ± 7.94 0.013 
DBP (mmHg) 82.69 ± 5.25 78.08 ± 3.25 0.010 
FMD (%) 0.30 ± 0.17 0.36 ± 0.17 0.172 
Hs-CRP (mg/L) 1.39 ± 1.14 1.20 ± 0.94 0.263 
ICAM-1 (ng/mL) 297.00 ± 122.30 265.23 ± 125.35 0.248 
VCAM-1 (ng/mL) 1008.31 ± 450.99 993.92 ± 447.42 0.657 
E-Selectin (ng/mL) 27.77 ± 15.89 25.49 ± 14.19 0.182 
IL-6 (ng/mL) 0.45 ± 0.16 0.46 ± 0.15 0.763 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FMD: Flow-mediated dilation; hsCRP: High-sensitivity C-reactive protein; 
ICAM-1: Intracellular adhesion molecule-1; VCAM-1: Vascular cell adhesion molecule-1; IL-6: Interleukin-6; Group comparisons were 
made using paired t-test (in case of normally distributed data) or Wilcoxon signed-ranks test (in case of non-normally distributed data). 
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findings might be attributed to the difference in the 
inclusion criteria applied by these two latter trials. It 
appears that hypotensive effects of PJ are more likely 
to be elicited in hypertensive patients, rather than 
patients with established CHD or metabolic 
syndrome. Moreover, the overall findings of the trials 
conducted so far weigh in favor of the beneficial effect 
of PJ consumption on BP. 
The hypotensive properties of PJ could be 
ascribed to the promising antioxidant properties of 
phytochemicals present in this complex juice. 
Oxidative stress is known to play a key role in the 
pathogenesis of hypertension.35 Increased levels of 
oxidants have been shown in different experimental 
models of hypertension.36-39 Detrimental effects of 
oxidative stress are mainly due to the interaction of 
reactive oxygen species (ROS) (in particular 
superoxide anion) with vital cellular components, 
lipids, and proteins, which leads to endothelial 
dysfunction and vascular resistance. In addition, 
ROS interfere with the production and vasodilatory 
actions of endothelium-derived nitric oxide (NO) 
via attenuating NO synthase (NOS) activity and 
enhancing NO breakdown.40,41 Epidemiological 
evidence has indicated that diets rich in natural 
antioxidants are associated with a reduced risk of 
developing hypertension and cardiovascular 
events.42,43 A plethora of studies have confirmed the 
considerable antioxidant and radical scavenging 
effects of PJ, which are mainly due to the 
anthocyanins and hydrolysable tannins present in 
the fruit. Interestingly, it has been suggested that 
some 50% of the total antioxidant activity of PJ is 
exerted by a specific ellagitannin, named 
punicalagin.16 Intestinal hydrolysis of punicalagin 
yields ellagic acid; the latter being a strong 
antioxidant compound.44 
Apart from antioxidant properties, PJ may lower 
BP through a direct interaction with ACE. As 
referred above, a significant reduction in the activity 
of serum ACE has been observed in hypertensive 
patients following PJ consumption.20Besides, in an 
animal study by Mohan et al. PJ administration 
attenuated angiotensin II-induced hypertension in 
diabetic rats, and also blocked the effects of different 
catecholamines on arterial BP and vasoreactivity. 
Furthermore, chronic administration of PJ 
counterbalanced the increased ACE activity in 
diabetic hypertensive rats.45 In spite of these positive 
reports, the ACE inhibitory effect of PJ needs to be 
further explored as Lynn et al. failed to report any 
change in serum ACE concentration following PJ 
consumption for 4 weeks.22 
Another primary outcome measure that was 
evaluated by the present trial was changes in 
endothelium-dependent flow-mediated dilation. 
Our results did not indicate any improvement in 
FMD and this is in agreement with our recent 
report on the effects of 2-week PJ intake.24 
However, findings from another trial indicated 
significant improvement in both endothelium-
dependent and –independent (nitroglycerin-
induced) dilation after 4 h of PJ consumption. In 
addition, this increased vasodilation was persisted 
until the end of supplementation period  
(1 month).25 In the present study, biomarkers of 
endothelial function, namely ICAM-1, VCAM-1, 
and E-selectin, remained statistically unaltered 
compared to baseline levels. It should be noticed 
that alterations in the circulating levels of these 
biomarkers is more likely to be exerted by chronic, 
rather than single dose, consumption of PJ and 
needs a longer term evaluation to allow the turnover 
of previously released proteins and observation of 
possible changes in the expression and subsequent 
release of these markers due to PJ consumption. 
This notion is corroborated by our previous study 
which showed a decreasing trend in serum levels of 
the aforementioned biomarkers following 
consumption of PJ.24 
The present study has certain limitations that 
need to be acknowledged. This study did not 
include a control group. Therefore, our findings 
might have been confounded by bias. In addition, 
the present trial was conducted in pilot scale and 
with a small population size. This small size could 
potentially account for lack of detecting significant 
difference despite the increasing trend in FMD and 
decreasing trends in serum CRP, ICAM-1, VCAM-
1, and E-selectin levels. With respect to these 
limitations, findings of the present trial may not be 
generalizable to the general population and should 
be interpreted with caution. 
In conclusion, the key finding to emerge from the 
present study is the acute hypotensive effect of PJ in 
hypertensive patients. While this trial is not a 
substitution for well-designed randomized controlled 
trials, it generates a hypothesis and motivates further 
research on this topic. Future large-scale 
investigations are indeed warranted in order to obtain 
a mechanistic understanding on this observed 
hypotensive activity. 
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